An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting

Trial Profile

An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Human skin replacement (Primary)
  • Indications Burns; Skin disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Stratatech
  • Most Recent Events

    • 19 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 10 Mar 2015 Top-line results published in the Media Release.
    • 10 Mar 2015 Primary endpoint (Percent area of the StrataGraft treatment site requiring autografting by day 28) has been met, according to Stratatech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top